Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Pucotenlimab in EGFR+ Advanced Gastric/GEJ Adenocarcinoma
NCT07692334Phase 2Not yet recruiting
- Sponsor
- West China Second University Hospital
- Start
- Jul 2026
- Primary completion
- Sep 2027
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by West China Second University Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07692334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692334.